Eileen’s market-leading experience, practical advice and industry insight in intellectual property and regulatory law make her a go-to advisor for life sciences clients.
Chair of Torys’ Intellectual Property and Food and Drug Regulatory practices, Eileen is one of a handful of Canadian lawyers who advise on regulatory clearance and intellectual property protection of products. Across the life science sector—including medicines, medical devices, medtech -—Eileen helps clients identify IP and regulatory assets, obtain and maintain market exclusivity, exploit IP assets and enforce their IP rights.
Eileen has particular expertise in the realm of pricing of pharmaceuticals, including the pricing of patented medicines and the jurisdiction of the PMPRB.
Agenda: Day 1 Oct 5, 2020
PMPRB ’22 GUIDELINES – WHAT DO WE KNOW SO FAR? SPECIAL Q&A
The PMPRB released its revised draft Guidelines on October 6th, making big news for the industry! Gain a better understanding of the details to prepare your senior management team both in Canada and internationally. Take away new perspectives and deepen your knowledge on:
- How the guidelines have been ‘updated’ given previous litigation
- Is what was formerly a ‘competition bureau’ approach applicable to drug pricing?
- What does TRUE access mean?
- Which arguments are acceptable in the face of future manufacturer investigations?
Set yourself up for success with answers to your toughest PMPRB questions.
Agenda: Day 2 Oct 6, 2020